Unlock stock picks and a broker-level newsfeed that powers Wall Street.

OTC Markets OTCPK - Delayed Quote USD

EBOS Group Limited (EBOSY)

Compare
41.94
-5.06
(-10.77%)
At close: April 11 at 4:00:00 PM EDT
Loading Chart for EBOSY
  • Previous Close 47.00
  • Open 47.00
  • Bid 40.72 x --
  • Ask 45.82 x --
  • Day's Range 47.00 - 47.00
  • 52 Week Range 31.50 - 47.00
  • Volume 17
  • Avg. Volume 0
  • Market Cap (intraday) 4.329B
  • Beta (5Y Monthly) 0.25
  • PE Ratio (TTM) 22.92
  • EPS (TTM) 1.83
  • Earnings Date Jul 13, 2025 - Jul 17, 2025
  • Forward Dividend & Yield 0.80 (1.90%)
  • Ex-Dividend Date Mar 3, 2025
  • 1y Target Est --

EBOS Group Limited engages in the marketing, wholesale, and distribution of healthcare, medical, pharmaceutical, and animal care products in Australia, Southeast Asia, and New Zealand. It operates through Healthcare and Animal Care segments. The company provides healthcare logistics; medication management solutions; pharmacy management software; loyalty, generics, compliance, business intelligence, and store software services; and health communications, programs, and consultancy services. It also offers community based health care services and programs; vitamins, minerals and supplements, herbal and fruit teas, and natural toothpastes, as well as functional foods, including molasses and manuka honey; Pharmacy Choice, a five step integrated retail program for independent pharmacies; and healthSAVE, a community pharmacy banner that helps members drive their retail businesses. In addition, the company supplies health and wellness products to public and private hospitals, day surgeries, general practice, aged care facilities, specialist clinics, government, and non-profit health agencies, as well as clinically essential products; and provides pharmacy services to private and public hospitals, cancer centers, correctional facilities, and veterinary clinics. Further, it offers allografts solutions; healthcare distribution, warehousing, clinical trial management, and product registration services; clinical trial logistics; aesthetic healthcare devices, medical-grade cosmeceuticals, and injectables; and surgical devices and medical consumables. Additionally, the company provides pet nutrition, treats, clean-up, and grooming products and accessories; and wholesales veterinary products for companion animals, production animals, and equine athletes. The company was formerly known as Early Bros Dental & Surgical Supplies Ltd. and changed its name to EBOS Group Limited in 1986. EBOS Group Limited was incorporated in 1922 and is headquartered in Docklands, Australia.

www.ebosgroup.com

5,200

Full Time Employees

June 30

Fiscal Year Ends

Recent News: EBOSY

View More

Performance Overview: EBOSY

Trailing total returns as of 4/15/2025, which may include dividends or other distributions. Benchmark is S&P/NZX 50 INDEX GROSS ( GROSS (^NZ50) .

YTD Return

EBOSY
0.00%
S&P/NZX 50 INDEX GROSS ( GROSS (^NZ50)
7.77%

1-Year Return

EBOSY
33.14%
S&P/NZX 50 INDEX GROSS ( GROSS (^NZ50)
1.48%

3-Year Return

EBOSY
33.14%
S&P/NZX 50 INDEX GROSS ( GROSS (^NZ50)
1.69%

5-Year Return

EBOSY
33.14%
S&P/NZX 50 INDEX GROSS ( GROSS (^NZ50)
16.16%

Compare To: EBOSY

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: EBOSY

View More

Valuation Measures

Annual
As of 11/13/2024
  • Market Cap

    4.04B

  • Enterprise Value

    4.97B

  • Trailing P/E

    22.93

  • Forward P/E

    25.84

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.47

  • Price/Book (mrq)

    2.57

  • Enterprise Value/Revenue

    0.62

  • Enterprise Value/EBITDA

    13.63

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    1.95%

  • Return on Assets (ttm)

    4.15%

  • Return on Equity (ttm)

    10.37%

  • Revenue (ttm)

    12.6B

  • Net Income Avi to Common (ttm)

    245.86M

  • Diluted EPS (ttm)

    1.83

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    237.93M

  • Total Debt/Equity (mrq)

    70.12%

  • Levered Free Cash Flow (ttm)

    338.65M

Research Analysis: EBOSY

View More

Company Insights: EBOSY

Research Reports: EBOSY

View More

People Also Watch